Poor
Not Aligned
Patient Risk:
Low
Summary
Only the ingredient/description claim is supported by the provided label excerpt (DESCRIPTION). All other claims are pricing/coverage/program/switching assertions that are absent from the supplied labeling text, and multiple include specific numeric estimates (cost and discount percentages) that cannot be validated against the label.
Category Scores
Accurate Statements
Euthyrox is a brand-name tablet that contains the synthetic thyroid hormone levothyroxine.
Supported by label section 11 DESCRIPTION (contains levothyroxine sodium, synthetic crystalline T4).
Unsupported Statements
The cost of Euthyrox can vary widely depending on country/region factors such as pharmacy chains, national health-insurance coverage, and local regulations.
Not supported by the supplied FDA label sections.
Euthyrox dosage strength affects price such that higher milligram doses (e.g., 200 µg, 300 µg) are usually more expensive per tablet than common 25–100 µg doses.
Not supported by the supplied FDA label sections.
Euthyrox formulation (tablet vs. liquid) can affect price, with liquid or soft-gel preparations sometimes carrying a premium.
Not supported by the supplied FDA label sections.
Insurance/PBM coverage can affect out-of-pocket cost, including that some plans cover brand names at a lower copay or use generic levothyroxine.
Not supported by the supplied FDA label sections.
Quantity dispensed affects price such that bulk purchases (e.g., 90-day fills) can reduce the per-tablet cost.
Not supported by the supplied FDA label sections.
Special programs such as manufacturer coupons, patient assistance programs, or discount card services can lower the price of Euthyrox.
Not supported by the supplied FDA label sections.
In the US in 2024, brand-name Euthyrox is estimated to cost $30–$70 per 30-tablet bottle.
Not supported by the supplied FDA label sections.
In the US in 2024, brand-name Euthyrox is estimated to cost approximately $1–$2.30 per tablet.
Not supported by the supplied FDA label sections.
In the US in 2024, generic levothyroxine is estimated to cost $15–$35 per 30-tablet bottle.
Not supported by the supplied FDA label sections.
In the US in 2024, generic levothyroxine is estimated to cost approximately $0.50–$1.20 per tablet.
Not supported by the supplied FDA label sections.
In most countries, generic levothyroxine is available at a fraction of the brand price and is therapeutically equivalent.
Not supported by the supplied FDA label sections.
Many insurance plans list generic levothyroxine as the preferred (lower-copay) option.
Not supported by the supplied FDA label sections.
GoodRx, Blink Health, or manufacturer coupons can offer 10–30% off the list price.
Not supported by the supplied FDA label sections.
A 90-day supply often lowers the per-tablet price compared to 30-day refills.
Not supported by the supplied FDA label sections.
Some pharmaceutical companies run patient assistance programs for low-income patients.
Not supported by the supplied FDA label sections.
A prescriber can switch a patient to a generic or a lower-dose formulation if clinically appropriate.
Not supported by the supplied FDA label sections.
Contradictions
Important Omissions
No FDA-label-supported indication, dosage and administration, contraindications, warnings/precautions, adverse reactions, monitoring, administration instructions, or storage/handling were provided in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The included unsupported claims are primarily about pricing/coverage/programs and do not directly provide dosing or safety instructions within the supplied excerpts; therefore, no direct label-conflicting safety assertion can be identified from the provided information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are non-label information (pricing, insurance/PBM/coupons/programs, and switching guidance) including specific dollar and discount estimates that are absent from the provided FDA label excerpt.
Suggested Improvement
Limit label-verified claims to the DESCRIPTION-supported facts (e.g., active ingredient/strengths) and remove or clearly qualify all pricing/coverage/program/switching statements that are not present in the FDA-approved prescribing information.